Kite looks all set for a regulatory approval later this year for its CAR-T drug KTE-CI9 after the company published encouraging topline primary results.
Roche’s Mabthera (rituximab) blood cancer and inflammatory diseases drug faces cheaper competition for the first time in Europe after regulators approved a near-copy, or biosimilar, from Ce